Cardiac Markers are biomarkers used to evaluate heart function and identify blood chemicals associated with Myocardial infarction (MI), commonly known as heart attack. These biomarkers also help physicians to assess acute coronary syndromes and to identify and mange high-risk patients. The role of cardiac markers in the diagnosis, risk stratification and treatment of patients with myocardial injuries has continued to evolve.
Goldcrest Polychem offers two of the most significant cardiac markers today, the cardiac Troponin-I (CTnI) and Heart-type Fatty Acid Binding Protein (H-FABP).
Troponin I (CTnI)
Heart-type Fatty Acid Binding Protein
Goldcrest Polychem offers two of the most significant cardiac markers today, the cardiac Troponin-I (CTnI) and Heart-type Fatty Acid Binding Protein (H-FABP).
Troponin I (CTnI)
- the most sensitive and specific test for myocardial damage
- the cardiac troponins are sensitive, cardiospecific, and have become the cardiac marker of choice for patients with acute coronary syndrome
- offers levels of sensitivity and specificity for cardiomyocyte injury that are superior to those for the creatine kinase MB fraction (CK-MB), which exists in tissues other than myocardium
- a recent consensus guideline from the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) has redefined the diagnostic criteria for acute myocardial infarction. Cardiac markers and cardiac troponin, in particular, are central to the new definition of acute myocardial infarction. Under this new definition, the measurement of cardiac troponins becomes the new gold standard diagnostic indicator of myocardial injury
Heart-type Fatty Acid Binding Protein
- a reliable biomarker for superacute phase MI
- rapidly released from damaged cardiomyocytes into the circulation due to its small size
- significantly elevated above their threshold level within three hours after acute MI
- a sensitive biomarker and can be detected in the blood within one to three hours upon onset of symptoms